decisionhealth Newsletters, Part B News - 2014 Issue 9 (September)
Vicodin’s new DEA status could impact your NPPs, patients and practice flow
Subscribe or sign in to view the full article.
Article Overview
This article covers a federal drug rescheduling change involving hydrocodone combination products and its potential impact on non-physician practitioners, patients, and practice operations. It is relevant to clinicians, practice managers, and coding/compliance staff who need to understand how state scope-of-practice rules and controlled-substance prescribing requirements may be affected.
Why This Topic Matters
Controlled-substance scheduling changes can alter prescribing authority, documentation processes, and staff workflows across different states and provider types. Practices that prescribe pain medications need to know which requirements may change so they can avoid disruptions in patient care and maintain compliance.
What You Will Learn
- How a federal scheduling change may affect hydrocodone combination products
- Which types of non-physician practitioners may be affected by state scope-of-practice differences
- What general controlled-substance prescribing workflow considerations practices may need to review
- Why state-specific rules can matter when prescribing Schedule II medications
Who Should Read This
- Physicians
- Nurse practitioners
- Physician assistants
- Certified registered nurse anesthetists
- Practice managers
- Compliance staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com